Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARD | Q03181 | 1/20 | 0.38 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.33 |
| ▸ | FNTA | P49354 | 1/20 | 0.33 |
| ▸ | FNTB | P49356 | 1/20 | 0.33 |
| ▸ | PGGT1B | P53609 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2330478 | 0.76 | PPARD (0.42) | PPARDFNTAFNTBPGGT1BSMN1; SMN2 | |
| SCHEMBL10477629 | 0.75 | PPARD (0.39) | PPARDFNTAFNTBPGGT1BSMN1; SMN2 | |
| SCHEMBL27755360 | 0.75 | DGAT1 (0.36) | DGAT1 | |
| SCHEMBL2361032 | 0.75 | DGAT1 (0.36) | DGAT1 | |
| SCHEMBL10477630 | 0.72 | PPARD (0.39) | PPARDFNTAFNTBPGGT1BSMN1; SMN2 | |
| SCHEMBL8919404 | 0.70 | DGAT1 (0.45) | DGAT1 | |
| SCHEMBL3175318 | 0.68 | PPARD (0.41) | PPARDFNTAFNTBPGGT1BSMN1; SMN2 | |
| SCHEMBL16485863 | 0.68 | GAA (0.48) | DGAT1SMN1; SMN2TP53 | |
| SCHEMBL2325563 | 0.68 | LMNA (0.45) | PPARD | |
| SCHEMBL1199775 | 0.67 | PPARD (0.52) | PPARDFNTAFNTBPGGT1BTP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1904455-B1 | PYRIDAZINE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2011-08-17 | — | — | EP | disclosed |
| US-7678795-B2 | Pyridazines as 11b-HSD1 inhibitors | HOFFMAN-LA ROCHE INC. (US) | 2010-03-16 | — | — | US | disclosed |
| US-20070010519-A1 | New pyridazines as 11B-HSD1 inhibitors | HOFFMANN-LA ROCHE INC. | 2007-01-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070010519-A1 | New pyridazines as 11B-HSD1 inhibitors | HSD11B1, HSD17B1, HSD17B11 | PPARD 503/4885DGAT1 3201/4885FNTA 2767/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.